- Home
- PRQR vs LRMR Comparison
PRQR vs LRMR Comparison
Compare PRQR & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- LRMR
- Stock Information
- Founded
- PRQR 2012
- LRMR N/A
- Country
- PRQR Netherlands
- LRMR United States
- Employees
- PRQR 166
- LRMR N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- PRQR Health Care
- LRMR Health Care
- Exchange
- PRQR Nasdaq
- LRMR Nasdaq
- Market Cap
- PRQR 244.4M
- LRMR 204.9M
- IPO Year
- PRQR 2014
- LRMR N/A
- Fundamental
- Price
- PRQR $2.26
- LRMR $3.21
- Analyst Decision
- PRQR Strong Buy
- LRMR Strong Buy
- Analyst Count
- PRQR 8
- LRMR 7
- Target Price
- PRQR $8.88
- LRMR $17.86
- AVG Volume (30 Days)
- PRQR 342.1K
- LRMR 1.1M
- Earning Date
- PRQR 08-07-2025
- LRMR 08-06-2025
- Dividend Yield
- PRQR N/A
- LRMR N/A
- EPS Growth
- PRQR N/A
- LRMR N/A
- EPS
- PRQR N/A
- LRMR N/A
- Revenue
- PRQR $21,212,711.00
- LRMR N/A
- Revenue This Year
- PRQR N/A
- LRMR N/A
- Revenue Next Year
- PRQR N/A
- LRMR N/A
- P/E Ratio
- PRQR N/A
- LRMR N/A
- Revenue Growth
- PRQR 85.91
- LRMR N/A
- 52 Week Low
- PRQR $1.07
- LRMR $1.61
- 52 Week High
- PRQR $4.62
- LRMR $10.25
- Technical
- Relative Strength Index (RSI)
- PRQR 56.82
- LRMR 55.23
- Support Level
- PRQR $2.27
- LRMR $3.11
- Resistance Level
- PRQR $2.51
- LRMR $3.40
- Average True Range (ATR)
- PRQR 0.13
- LRMR 0.24
- MACD
- PRQR -0.00
- LRMR -0.03
- Stochastic Oscillator
- PRQR 51.49
- LRMR 45.98
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.